{
  "id": "albi_grade",
  "title": "ALBI (Albumin-Bilirubin) Grade for Hepatocellular Carcinoma (HCC)",
  "description": "Predicts survival in hepatocellular carcinoma patients based on objective measures of liver function (albumin and bilirubin)",
  "category": "oncology",
  "version": "2015",
  "parameters": [
    {
      "name": "albumin",
      "type": "float",
      "required": true,
      "description": "Serum albumin level in g/L",
      "validation": {
        "min": 10.0,
        "max": 60.0
      },
      "unit": "g/L"
    },
    {
      "name": "bilirubin",
      "type": "float",
      "required": true,
      "description": "Serum bilirubin level in μmol/L",
      "validation": {
        "min": 1.0,
        "max": 1000.0
      },
      "unit": "μmol/L"
    }
  ],
  "result": {
    "name": "albi_score",
    "type": "float",
    "unit": "score",
    "description": "ALBI score value"
  },
  "interpretation": {
    "ranges": [
      {
        "min": -10.0,
        "max": -2.60,
        "stage": "Grade 1",
        "description": "Best liver function",
        "interpretation": "ALBI Grade 1 (≤-2.60): Best liver function and prognosis. Median survival 18.5-85.6 months. Good candidate for aggressive treatments including surgery, transplantation, and systemic therapy."
      },
      {
        "min": -2.60,
        "max": -1.39,
        "stage": "Grade 2",
        "description": "Intermediate liver function",
        "interpretation": "ALBI Grade 2 (>-2.60 to ≤-1.39): Intermediate liver function and prognosis. Median survival 5.3-46.5 months. Consider treatment options based on overall condition and tumor characteristics."
      },
      {
        "min": -1.39,
        "max": 10.0,
        "stage": "Grade 3",
        "description": "Poor liver function",
        "interpretation": "ALBI Grade 3 (>-1.39): Poor liver function and prognosis. Median survival 2.3-15.5 months. Limited treatment options, focus on supportive care and palliative measures."
      }
    ]
  },
  "references": [
    "Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550-8.",
    "Hiraoka A, Michitaka K, Kumada T, et al. Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer. 2017;6(4):325-336.",
    "Chen B, Lin S. Albumin-bilirubin (ALBI) score at admission predicts possible outcomes in patients with acute-on-chronic liver failure. Medicine (Baltimore). 2017;96(24):e7142."
  ],
  "formula": "ALBI = (log10 bilirubin × 0.66) + (albumin × -0.085), where bilirubin is in μmol/L and albumin in g/L",
  "notes": [
    "ALBI grade uses only objective laboratory values (no subjective variables)",
    "Alternative to Child-Pugh grade with better objectivity",
    "Validated in multiple international cohorts",
    "Grade 1: ≤-2.60 (best prognosis, 18.5-85.6 months median survival)",
    "Grade 2: >-2.60 to ≤-1.39 (intermediate prognosis, 5.3-46.5 months)",
    "Grade 3: >-1.39 (poor prognosis, 2.3-15.5 months)",
    "Useful for treatment selection and prognostication",
    "Correlates with treatment tolerance and response",
    "Can guide decisions for surgery, transplantation, and systemic therapy",
    "Particularly useful in HCC staging and management",
    "More objective than Child-Pugh (no ascites or encephalopathy assessment)",
    "Applicable to patients with and without cirrhosis"
  ]
}